Lung carcinoma with ALK rearrangement

From Libre Pathology
Revision as of 03:03, 21 September 2017 by Abraham (talk | contribs) (→‎General)
Jump to navigation Jump to search

Lung carcinoma with ALK rearrangement is subset of lung adenocarcinoma.

General

ALK (Anaplastic lymphoma receptor tyrosine kinase)

  • Approximately 1-5% non-small cell lung carcinoma.[1]
    • Typically seen in nonsmokers and younger age patients.
    • Can be treated with crizotinib.[2]

Microscopic

Features:[1]

  • Adenocarcinoma - at least focally.
  • Solid signet-ring cell pattern - common.
  • Mucinous cribriform pattern - common.

DDx:

Images

IHC

Features:[1]

Molecular

  • EML4-ALK fusion -- inv(2)(p21p23).[5]

Notes:

See also

References

  1. 1.0 1.1 1.2 Yoshida, A.; Tsuta, K.; Nakamura, H.; Kohno, T.; Takahashi, F.; Asamura, H.; Sekine, I.; Fukayama, M. et al. (Aug 2011). "Comprehensive histologic analysis of ALK-rearranged lung carcinomas.". Am J Surg Pathol 35 (8): 1226-34. doi:10.1097/PAS.0b013e3182233e06. PMID 21753699.
  2. Crystal, AS.; Shaw, AT. (Mar 2011). "New targets in advanced NSCLC: EML4-ALK.". Clin Adv Hematol Oncol 9 (3): 207-14. PMID 21475126.
  3. Lopes, LF.; Bacchi, CE. (Jul 2012). "Anaplastic lymphoma kinase gene rearrangement in non-small-cell lung cancer in a Brazilian population.". Clinics (Sao Paulo) 67 (7): 845-7. PMID 22892933.
  4. Takamochi, K.; Takeuchi, K.; Hayashi, T.; Oh, S.; Suzuki, K. (2013). "A rational diagnostic algorithm for the identification of ALK rearrangement in lung cancer: a comprehensive study of surgically treated Japanese patients.". PLoS One 8 (8): e69794. doi:10.1371/journal.pone.0069794. PMID 23936355.
  5. Li, Y.; Ye, X.; Liu, J.; Zha, J.; Pei, L. (Jan 2011). "Evaluation of EML4-ALK fusion proteins in non-small cell lung cancer using small molecule inhibitors.". Neoplasia 13 (1): 1-11. PMID 21245935.
  6. 6.0 6.1 Gainor, JF.; Varghese, AM.; Ou, SH.; Kabraji, S.; Awad, MM.; Katayama, R.; Pawlak, A.; Mino-Kenudson, M. et al. (Aug 2013). "ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer.". Clin Cancer Res 19 (15): 4273-81. doi:10.1158/1078-0432.CCR-13-0318. PMID 23729361.